NCCN 2025 Lung Cancer Congress

NCCN would like to thank the outstanding faculty who are presenting, and you for attending this educational program.

We hope you find the information useful to your practice, and we encourage you to attend future NCCN educational initiatives.

Contents	Pages
Agenda	1
Accreditation Information	2 – 7
Supporting Organizations	*5*
How to Claim Credit	*7*
Disclosure Information	8 – 12
Speaker Biographies	13 – 18
Learn More about NCCN	19

National Comprehensive Cancer Network®

NCCN 2025 Lung Cancer Congress
Philadelphia, PA | *In-Person & Virtual*
Friday, November 7, 2025

Agenda

7:45 AM – 8:30 AM	**Registration, Breakfast, and Exhibits**
8:30 AM – 8:35 AM	**Opening Remarks** | Gregory J. Riely, MD, PhD, *Memorial Sloan Kettering Cancer Center*
8:35 AM – 9:10 AM	**Managing Small Cell Lung Cancer: Practical Strategies for Primary and Subsequent Systemic Therapy** Christine L. Hann, MD, PhD, *Johns Hopkins Kimmel Cancer Center*
9:10 AM – 9:40 AM	**The Role of Radiation Therapy in Small Cell Lung Cancer** Aditya Juloori, MD, *The UChicago Medicine Comprehensive Cancer Center*
9:40 AM – 9:50 AM	**Panel Q&A |** Christine L. Hann, MD, PhD & Aditya Juloori, MD
9:50 AM – 10:10 AM	**Break and Exhibits**
10:10 AM – 10:40 AM	**Systemic Therapy in Early-Stage, Wild-Type Non-Small Cell Lung Cancer: Current Standards and Practical Applications** Dwight H. Owen, MD, MS, *The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute*
10:40 AM – 11:10 AM	**Targeted Therapy for Early-Stage, *EGFR*- and ALK-Positive Non-Small Cell Lung Cancer: Precision Treatment and Strategies** Charu Aggarwal, MD, MPH, *Abramson Cancer Center at the University of Pennsylvania*
11:10 AM – 12:10 PM	**Multidisciplinary Coordination and Treatment Sequencing in Non-Small Cell Lung Cancer Care** Jonathan E. Dowell, MD, *UT Southwestern Simmons Comprehensive Cancer Center* Dawn Owen, MD, PhD, *Mayo Clinic Comprehensive Cancer Center* Jane Yanagawa, MD, *UCLA Jonsson Comprehensive Cancer Center*
12:10 PM – 1:10 PM	**Lunch and Exhibits**
1:10 PM – 1:40 PM	**Biomarker Testing in Non-Small Cell Lung Cancer: What's New and What's Next** Ana Lucia Ruano Mendez, MD, *Huntsman Cancer Institute at the University of Utah*
1:40 PM – 2:10 PM	**Managing *EGFR*-Positive Non-Small Cell Lung Cancer Across the Treatment Spectrum: A Team-Based Approach** Melina E. Marmarelis, MD, MSCE, *Abramson Cancer Center at the University of Pennsylvania*
2:10 PM – 2:40 PM	**Evolving Evidence and Practical Integration of Radiation Therapy in Metastatic Non-Small Cell Lung Cancer** Billy W. Loo, MD, PhD, *Stanford Cancer Institute*
2:40 PM – 3:10 PM	***KRAS* Mutations in Non-Small Cell Lung Cancer: Current Landscape and Evolving Therapies** Hossein Borghaei, DO, MS, *Fox Chase Cancer Center*
3:10 PM – 3:30 PM	**Break and Exhibits**
3:30 PM – 4:00 PM	**Rare Targets and Novel Therapies in Non-Small Cell Lung Cancer: Navigating New TKIs and Uncommon Oncogenic Drivers** Aakash Desai, MD, MPH, *O'Neal Comprehensive Cancer Center at UAB*
4:00 PM – 4:30 PM	**Toxicity and Symptom Management Related to Oral Agents and TKIs: What Every Team Member Should Know** Beth Sandy, MSN, CRNP, FAPO, *Abramson Cancer Center at the University of Pennsylvania*
4:30 PM – 5:00 PM	**Lab Monitoring Made Simple: A Practical Guide for the Oncology Care Team** Sophia Gilardone, PharmD, BCOP, *Abramson Cancer Center at the University of Pennsylvania*
5:00 PM	**Closing Remarks** | Gregory J. Riely, MD, PhD, *Memorial Sloan Kettering Cancer Center*

All times listed as Eastern Standard Time (UTC/GMT -5).

Program Overview

The *NCCN 2025 Lung Cancer Congress* is designed to provide the interprofessional oncology care team with practical guidance on the latest updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), novel and emerging therapies, recent clinical research, and strategies to align new developments with current standards of care. This activity aims to support the implementation of evidence-based, team-driven approaches to improve outcomes for patients with lung cancer, particularly in community-based practice.

Intended Audience

This program is designed to meet the educational needs of physicians, nurse practitioners, nurses, pharmacists, physician associates, and other relevant health care professionals who treat patients with lung cancer.

Goal of Education

The goal of the *NCCN 2025 Lung Cancer Congress* is to ensure that members of the interprofessional oncology care team have the knowledge and skills necessary to:

- Apply the current standards of oncology care and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to optimize the management of patients with lung cancer.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with lung cancer.
- Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with lung cancer.

Session Learning Objectives

Following each session, participants should be able to:

Managing Small Cell Lung Cancer: Practical Strategies for Primary and Subsequent Systemic Therapy

- Evaluate and apply evidence-based therapeutic strategies for first-line and subsequent treatment of SCLC.
- Assess the practical considerations, challenges, and strategies for implementing tarlatamab in the community oncology setting.
- Identify current and emerging clinical trials and pipeline agents in SCLC and integrate this knowledge into shared decision-making for eligible patients.

The Role of Radiation Therapy in Small Cell Lung Cancer

- Explain the indications, timing, and integration of radiation therapy for treatment of limited- and extensive-stage SCLC.
- Evaluate the risks and benefits of prophylactic cranial irradiation and apply the NCCN Guidelines for its use in preventing brain metastases in patients with SCLC.
- Identify patient-specific and logistical considerations that impact the delivery of radiation therapy in community and academic settings.

Session Learning Objectives *(continued)*

Systemic Therapy in Early-Stage, Wild-Type Non-Small Cell Lung Cancer: Current Standards and Practical Applications

- Describe current NCCN Guidelines recommendations for systemic therapy in early-stage, wild-type NSCLC.
- Evaluate clinical trial evidence supporting the use of neoadjuvant and adjuvant immunotherapy.
- Apply practical, team-based strategies for integrating immunotherapy into treatment planning for early-stage, wild-type NSCLC.

Targeted Therapy for Early-Stage, *EGFR*- and ALK-Positive Non-Small Cell Lung Cancer: Precision Treatment and Strategies

- Summarize NCCN Guidelines recommendations and pivotal clinical trial data guiding the use of targeted therapy in early-stage *EGFR*- and ALK-positive NSCLC.
- Explain the rationale for avoiding immunotherapy in patients with oncogenic driver mutations and the impact on treatment selection in early-stage disease.
- Implement a biomarker-driven, multidisciplinary approach to selecting and sequencing surgery and systemic therapy for patients with *EGFR*- or ALK-positive early-stage NSCLC.

Multidisciplinary Coordination and Treatment Sequencing in Non-Small Cell Lung Cancer Care

- Identify the roles and responsibilities of the multidisciplinary care team in the diagnosis, staging, and molecular testing of early-stage NSCLC.
- Outline the recommended sequencing of systemic therapy, radiation, and surgery in the management of early-stage and locally advanced NSCLC.
- Implement effective communication strategies among oncology team members to optimize individualized treatment planning and minimize delays in care delivery for patients with early-stage and locally advanced NSCLC.

Biomarker Testing in Non-Small Cell Lung Cancer: What's New and What's Next

- Describe recent advancements in biomarker testing for lung cancer, including emerging predictive and prognostic markers relevant to therapy selection.
- Interpret current NCCN Guidelines recommendations for biomarker testing in lung cancer and apply them to clinical decision-making.
- Assess barriers to biomarker testing in various care settings and identify strategies to optimize timely and accurate testing.

Managing *EGFR*-Positive Non-Small Cell Lung Cancer Across the Treatment Spectrum: A Team-Based Approach

- Describe current NCCN Guidelines recommendations and emerging data for first-line and subsequent treatment of *EGFR*-mutated NSCLC.
- Identify mechanisms of resistance and strategies for treatment sequencing in patients with disease progression or relapsed *EGFR*-positive NSCLC.
- Differentiate treatment approaches for *EGFR*-positive driver-negative NSCLC and apply appropriate therapeutic strategies based on molecular testing.

Session Learning Objectives *(continued)*

Evolving Evidence and Practical Integration of Radiation Therapy in Metastatic Non-Small Cell Lung Cancer

- Describe the current and evolving role of radiation therapy in the multidisciplinary management of metastatic non-small cell lung cancer, including palliative and disease-directed settings.
- Interpret key findings from recent and ongoing phase III trials evaluating stereotactic body radiotherapy and other advanced techniques in oligometastatic and brain metastatic disease.
- Evaluate clinical considerations and trial-based evidence supporting the selective use of radiation therapy in patients with low-volume, asymptomatic metastatic NSCLC, and explore future directions in this setting.

***KRAS* Mutations in Non-Small Cell Lung Cancer: Current Landscape and Evolving Therapies**

- Distinguish between *KRAS* mutation subtypes in NSCLC and describe their prognostic and predictive significance.
- Evaluate the clinical data supporting the current targeted therapies for *KRAS* mutations.
- Identify emerging therapeutic strategies and clinical trials targeting *KRAS* mutations and apply this knowledge to support patient access and eligibility for novel treatments.

Rare Targets and Novel Therapies in Non-Small Cell Lung Cancer: Navigating New TKIs and Uncommon Oncogenic Drivers

- Identify rare oncogenic drivers in NSCLC and describe their relevance to therapy selection.
- Evaluate the efficacy, safety, and clinical application of newly approved and investigational tyrosine kinase inhibitors in patients with uncommon driver mutations.
- Implement best practices for molecular profiling and multidisciplinary coordination to optimize the timely identification of patients with rare targets.

Toxicity and Symptom Management Related to Oral Agents and TKIs: What Every Team Member Should Know

- Identify common treatment-related toxicities in patients with lung cancer.
- Describe strategies for patient education and monitoring, managing, and mitigating key symptoms.
- Implement team-based strategies for assessing and managing treatment-related toxicities and symptoms in lung cancer, leveraging the roles of the interprofessional oncology care team to optimize patient outcomes.

Lab Monitoring Made Simple: A Practical Guide for the Oncology Care Team

- Identify key laboratory tests required for monitoring patients receiving oral therapies.
- Differentiate lab monitoring requirements based on treatment class, mechanisms of action, and toxicity profile to ensure safe and effective patient management.
- Apply practical, team-based strategies to streamline lab monitoring in settings with limited access to dedicated oncology pharmacy support, including tools and workflows for the interprofessional team.

CE Supporters

This activity is supported by educational grants from:

- Exact Sciences
- Genentech, a member of the Roche Group
- Johnson & Johnson

This activity is supported by independent medical education grants from:

- AbbVie
- Boehringer Ingelheim Pharmaceuticals, Inc.

Accreditation Statements

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 6.75 *AMA PRA Category 1 Credits™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 6.75 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 6.75 contact hours (0.675 CEUs) of continuing education credit. UAN: JA4008196-0000-25-110-L01-P

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Maintenance of Certification (MOC)
This activity has been registered to offer credit in the American Board of Pathology's (ABPath) Continuing Certification program. Successful completion of this CME activity enables the participant to earn up to 6.75 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.

Accreditation Statements *(continued)*

American Board of Surgery Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Thoracic Surgery (CC)
Successful completion of this CME activity enables the learner to earn credit toward the CME requirements of the American Board of Thoracic Surgery's Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABTS credit.

American Board of Medical Specialties (MOC)
Through the American Board of Medical Specialties ("ABMS") MOC Initiative to create a wide array of Maintenance of Certification ("MOC") Activities through the ABMS MOC Directory, the ***NCCN 2025 Lung Cancer Congress*** *has met the MOC requirements as a* ***MOC Part II CME Activity*** *(apply toward general CME requirement) by the following ABMS Member Boards:*

MOC Part II CME Activity
Radiology

Permission to Upload Credits
For ABIM, ABPath, ABS, and ABTS MOC points, your information will be shared with your board through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your board records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these boards via JA-PARS.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 6.75 CE contact hours.

Activity code: C00065090 Approval Number: 250003386

Oncology Data Specialists
The "***NCCN 2025 Lung Cancer Congress***" program supports 6.75 CE hours of which 6.75 hours meet the Category A requirement. This program has been assigned the following event number: 2025-274.

The ***"NCCN 2025 Lung Cancer Congress"*** program supports **6.75 CEIP hours** of which 6.75 **hours** meet the *Category A* requirement.

This program has been assigned the following event number*:* ***2025-274IP***

How to Claim CE Credit

Before claiming CE credit, please ensure that you have an NCCN account and will receive the correct type of credit.

1. Log-in at NCCN.org.
   - *If you do not have an NCCN account, click Create Account.*
2. Under Account Settings, click **Edit Account → Profile**.
3. Verify that your **User Type** matches the type of credit that you will claim.
   - Physician/Surgeon/Oncologist: *AMA PRA Category 1 Credits*™; MOC points, if applicable*
   - Physician Assistant: AAPA Category 1 CME credits
   - Pharmacist: ACPE contact hours**
   - Nurse Practitioner: ANCC contact hours
   - Clinical Nurse Specialist: ANCC contact hours
   - Nurse/Oncology Nurse: ANCC contact hours; CCM clock hours
   - Case Manager (Nurse): ANCC contact hours; CCM clock hours
   - Case Manager (Non-Nurse): CCM clock hours
   - Tumor Registrar: NCRA CE hours
   - All Other User Types: certificate of participation
4. Scroll down and click **Save** if you make any changes.

Credit claiming will open at the conclusion of the Congress. (Friday, November 7, 2025, 5:00 PM EST.)

To claim your credits, you will need to log-in with the same email address used for program registration.

1. Log-in at **education.nccn.org/lung2025**.
2. Click the **Take Course** button.
3. Follow the prompts to complete the post-test and evaluation and claim your credits.

****Physicians claiming ABIM, ABPath, ABS, or ABTS MOC points***: ABIM/ABPath/ABS/ABTS MOC points are reported to ABIM/ABPath/ABS/ABTS after you have completed the post-test and evaluation and claimed your credits. **Be sure to enter your learner/diplomate ID and date of birth when prompted in the evaluation**. Your credit cannot be reported without this information. By sharing your learner/diplomate ID and date of birth, you are giving NCCN permission to use this information/data to report your participation to ABIM/ABPath/ABS via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

*****Pharmacists***: **You must complete all requirements for credit by December 17, 2025.** Continuing pharmacy education credit is reported to the CPE Monitor after you have completed the post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth. Your credit cannot be reported without this information.

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose **ALL** financial relationships they have had in the past **24 months** with ineligible companies. The ACCME *Standards for Integrity and Independence* require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past **24 months** are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of **ALL** financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

NCCN Staff Disclosures

None of the planners for this educational activity have **relevant** financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Congress Planning Committee

The faculty listed below have **no relevant financial relationships** with ineligible companies to disclose.

Michael Seidman, MD

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Charu Aggarwal, MD, MPH ***(Presenting Faculty)***
AbbVie, Inc.: Consulting Fee
Arcus Biosciences: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
Boehringer Ingelheim GmbH: Consulting Fee
Daiichi Sankyo, Inc./AstraZeneca Pharmaceuticals LP: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Loxo@Lilly: Consulting Fee
Novocure: Consulting Fee
Merck Sharp & Dohme: Consulting Fee
Pfizer Inc.: Consulting Fee
Sanofi/Regeneron: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Hossein Borghaei, DO, MS ***(Presenting Faculty)***
AbbVie, Inc.: Consulting Fee; Scientific Advisor
Amgen Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Astellas Pharma US, Inc.: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
Axiom: Consulting Fee; Scientific Advisor
Bayer HealthCare: Consulting Fee; Scientific Advisor
BeiGene: Consulting Fee; Scientific Advisor
BerGenBio: Consulting Fee; Scientific Advisor
BioNTech: Consulting Fee; Scientific Advisor
Boehringer Ingelheim GmbH: Consulting Fee; Scientific Advisor
Bristol Myers Squibb: Consulting Fee; Grant/Research Support; Scientific Advisor
Daiichi- Sankyo Co.: Consulting Fee; Honoraria; Scientific Advisor
Eli Lilly and Company: Consulting Fee; Grant/Research Support; Scientific Advisor
EMD Serono: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Scientific Advisor
Genmab: Consulting Fee; Scientific Advisor
Gilead Sciences, Inc.: Consulting Fee; Scientific Advisor
Grid Therapeutics: Consulting Fee; Scientific Advisor
Guardant Health: Consulting Fee; Scientific Advisor
Incyte Corporation: Scientific Advisor
Inspirna (formerly RGENIX): Equity Interest/Stock Options; Scientific Advisor
IO Bioetech: Consulting Fee; Scientific Advisor
iTeos Therapeutics: Consulting Fee; Scientific Advisor

Faculty Disclosures *(continued)*

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Hossein Borghaei, DO, MS ***(Presenting Faculty), continued***
Janssen Pharmaceutica Products, LP: Consulting Fee; Honoraria; Scientific Advisor
Jazz Pharmaceuticals Inc.: Consulting Fee; Honoraria; Scientific Advisor
Merck & Co., Inc.: Consulting Fee; Scientific Advisor
Mirati Therapeutics, Inc.: Consulting Fee; Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee; Scientific Advisor
Novocure: Consulting Fee; Scientific Advisor
Natera: Consulting Fee; Scientific Advisor
Oncocyte: Consulting Fee; Scientific Advisor
PharmaMar: Consulting Fee; Scientific Advisor
Pfizer Inc.: Consulting Fee; Honoraria; Scientific Advisor
Puma Biotechnology: Consulting Fee; Scientific Advisor
RAPT Therapeutics Consulting Fee; Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Consulting Fee; Honoraria; Scientific Advisor
Servier: Scientific Advisor
Sonnet BioTherapeutics, Inc.: Equity Interest/Stock Options; Scientific Advisor
SpringWorks Therapeutics: Scientific Advisor
Summit Therapeutics Consulting Fee; Scientific Advisor
SystImmune, Inc.: Consulting Fee; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Scientific Advisor

Gregory J. Riely, MD, PhD ***(Congress Chair and Moderator)***
Amgen Inc.: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Roche Laboratories, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support

Presenting Faculty

The faculty listed below have **no relevant financial relationships** with ineligible companies to disclose.

Sophia Gilardone, PharmD, BCOP
Ana Lucia Ruano Mendez, MD

Faculty Disclosures *(continued)*

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Aakash Desai, MD, MPH
AbbVie, Inc.: Honoraria; Scientific Advisor
Amgen Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Bayer HealthCare: Honoraria; Scientific Advisor
Bristol Myers Squibb: Honoraria; Scientific Advisor
Eli Lilly and Company: Honoraria: Scientific Advisor
Foundation Medicine, Inc.: Honoraria; Scientific Advisor
Janssen Pharmaceutica Products, LP: Honoraria; Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Honoraria; Scientific Advisor

Jonathan E. Dowell, MD
Genentech, Inc.: Honoraria
Nuvation Bio, Inc.: Honoraria
Pfizer Inc.: Honoraria

Christine L. Hann, MD, PhD
AbbVie, Inc.: Consulting Fee
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Daiichi- Sankyo Co.: Consulting Fee; Grant/Research Support
Genentech, Inc.: Consulting Fee

Aditya Juloori, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
EMD Serono: Consulting Fee
GSK: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Consulting Fee

Billy W. Loo, MD, PhD
BeiGene: Scientific Advisor
Mevion Medical Systems: Honoraria

Melina E. Marmarelis, MD, MSCE
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Bayer HealthCare: Consulting Fee
Boehringer Ingelheim GmbH: Consulting Fee
Bristol Myers Squibb: Consulting Fee
Daiichi- Sankyo Co.: Consulting Fee
Eli Lilly and Company: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee; Grant/Research Support
Johnson & Johnson: Equity Interest/Stock Options
Merck & Co., Inc.: Equity Interest/Stock Options; Grant/Research Support
NEUVOGEN, Inc.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Consulting Fee

Faculty Disclosures *(continued)*

The faculty listed below have the following **relevant financial relationship(s)** with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Melina E. Marmarelis, MD, MSCE, ***continued***
Takeda Pharmaceuticals North America, Inc.: Consulting Fee
Thermo Fisher Scientific Inc.: Honoraria

Dawn Owen, MD, PhD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Varian Medical Systems, Inc.: Grant/Research Support

Dwight H. Owen, MD, MS
AbbVie, Inc.: Grant/Research Support
Amgen Inc.: Non-royalty Payments
AstraZeneca Pharmaceuticals LP: Non-royalty Payments
Bristol Myers Squibb: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Non-royalty Payments
Merck & Co., Inc.: Grant/Research Support
Onc.AI: Grant/Research Support
Palobiofarma LLC: Grant/Research Support
Pfizer Inc.: Grant/Research Support

Beth Sandy, MSN, CRNP
AbbVie, Inc.: Consulting Fee
Amgen Inc.: Product/Speakers Bureau
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau
Catalyst Pharmaceuticals, Inc.: Consulting Fee
Eli Lilly and Company: Honoraria
Janssen Pharmaceutica Products, LP: Consulting Fee; Product/Speakers Bureau
Jazz Pharmaceuticals Inc.: Product/Speakers Bureau
Merck & Co., Inc.: Product/Speakers Bureau
Pfizer Inc.: Consulting Fee

Jane Yanagawa, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor

Speaker Biographies

Gregory J. Riely, MD, PhD, is Vice-Chair, Clinical Research in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC), where he also serves as Ning Zhao and Ge Li Chair in Lung Cancer Research. Additionally, Dr. Riely holds a faculty position as Professor of Medicine at Weill Cornell Medical College.

Dr. Riely earned his medical degree and doctorate of philosophy from Case Western Reserve University. He completed his residency at New York-Presbyterian Hospital/Weill Cornell Medical Center and fellowship at the MSKCC Memorial Hospital for Cancer & Allied Diseases and Weill Cornell Medical College. He is board-certified in internal medicine, with a subspecialty in medical oncology.

Dr. Riely specializes in the treatment of thoracic malignancies, including lung cancer and thymic malignancies. His clinical research focuses on developing novel therapies by designing and conducting clinical trials. Dr. Riely serves as the Principal Investigator (PI) or co-PI for a number of ongoing clinical trials at MSKCC and has lectured and published extensively on these diseases.

Dr. Riely is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He previously served on the Thoracic Expert Panel for the American Joint Committee on Cancer.

Dr. Riely is Chair of the NCCN Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas Panel. He also serves on the *JNCCN* editorial board, as well as several committees for the NCCN Oncology Research Program.

Charu Aggarwal, MD, MPH, is the *Leslye Heisler Professor for Lung Cancer Excellence* at the University of Pennsylvania's Perelman School of Medicine, where she also serves as Section Chief of Thoracic and Head and Neck Oncology in the Division of Hematology-Oncology. An internationally recognized expert in precision medicine and thoracic oncology, Dr. Aggarwal specializes in the management of patients with lung cancer, with a research focus on biomarker discovery, liquid biopsy strategies, and the development of novel immunotherapeutic and targeted approaches.

Dr. Aggarwal has been at the forefront of integrating liquid biopsy into clinical practice, pioneering approaches for molecular profiling, minimal residual disease detection, and real-time disease monitoring to optimize patient outcomes. She leads patient-centered clinical trials that have shaped personalized treatment paradigms. She also serves as Associate Director of the Penn Center for Precision Medicine and Director of Precision Medicine Innovation at the Penn Center for Cancer Care Innovation (PC3I), where she leads strategic initiatives to implement cutting-edge technologies, including liquid biopsy platforms, into routine cancer care. Her work bridges scientific discovery and clinical application, driving innovation to deliver on the promise of individualized cancer therapies.

Speaker Biographies

Hossein Borghaei, DO, MS, is the Chief of Thoracic Medical Oncology, Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair in Thoracic Malignancies.

Dr. Borghaei earned his degree at Philadelphia College of Osteopathic Medicine and completed a residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in several clinical trials aimed at developing new antibody-based therapies and immunotherapies for patients with lung cancer.

In addition to his clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.

Dr. Borghaei is the co-chair of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG). He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei has also received the Robert Krigel Teaching Award at Fox Chase Cancer Center for his contributions to the fellowship program. He also chairs the Research Review Committee at Fox Chase Cancer Center.



Aakash Desai, MD, MPH, serves as an Assistant Professor of Medicine at the O'Neal Cancer Center, University of Alabama Birmingham. His pioneering research is primarily concentrated in the realm of evidence-based oncology, clinical trials, drug development, healthcare delivery, and quality of cancer care. He holds a particular interest in Thoracic Oncology and drug development.

Dr. Desai received his medical degree from B.J. Medical College, Ahmedabad, India. He then ventured overseas to acquire a Master's in Public Health from the University of Texas Health Science Center. This was followed by a residency and certification in Health Professions Education at the University of Connecticut. Dr. Desai's journey of specialization continued in 2020 at the globally recognized Mayo Clinic, Rochester, where he joined the fellowship program in oncology and hematology.

Throughout his career, Dr. Desai has been honored with a multitude of prestigious accolades reflecting his profound contribution to the field of medicine. These include the Conquer Cancer Foundation ASCO Young Investigator Award (2021), the International Association for the Study of Lung Cancer Early Career Award (2021), ASCO Merit Awards (2021 and 2022), Education Awards at the Targeted Therapies in Lung Cancer Conference (2022 and 2023), and the International Cancer Foundation scholarship for the ESMO Targeted Anticancer Therapies (TAT, 2022). His commitment to patient education was recognized with his appointment as a patient education ambassador for the Cancer GRACE Foundation for 2021-2022.

Dr. Desai is a member of the NCCN Non-Small Cell Lung Cancer/ Mesothelioma/Thymomas and Thymic Carcinomas Panel and the NCCN Digital Oncology Forum.

Speaker Biographies

Jonathan E. Dowell, MD, is Professor of Internal Medicine in the Division of Hematology/Oncology at UT Southwestern Simmons Comprehensive Cancer Center. He also holds the position of Chief of the Section of Hematology/Oncology at Dallas VA Medical Center.

Dr. Dowell earned his medical degree at the University of Chicago and completed his internal medicine training at UT Southwestern. He subsequently completed his fellowship in hematology and oncology at Vanderbilt University, where he received extensive mentorship in thoracic malignancies from leaders in that field.

Dr. Dowell specializes primarily in thoracic malignancies and is an active investigator in the clinical research program at UT Southwestern and co-directs the Thoracic Disease-Oriented Team.

Dr. Dowell is a member of the NCCN Guidelines Panel for Non-Small Cell Lung Cancer/Mesothelioma/ Thymomas and Thymic Carcinomas.



Sophia Gilardone, PharmD, BCOP, is a Clinical Pharmacy Specialist at the Hospital of the University of Pennsylvania. She has worked with the Thoracic Oncology group for the past three years specializing in lung, head & neck, and thyroid cancers.

Dr. Gilardone received her PharmD from the University of Illinois at Chicago, where she stayed on to complete her PGY1 Pharmacy Practice Residency. She went on to complete a PGY2 Oncology Pharmacy Residency at Moffitt Cancer Center.



Christine L. Hann, MD, PhD, is an Associate Professor of Medical Oncology and a practicing physician at Johns Hopkins Kimmel Cancer Center.

Dr. Hann completed her MD and PhD at Jefferson Medical College/Thomas Jefferson University, followed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer.

Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research.

Dr. Hann is a member of the NCCN Small Cell Lung Cancer Panel.

Speaker Biographies

Aditya Juloori, MD, is Assistant Professor of Radiation and Cellular Oncology at The UChicago Medicine Comprehensive Cancer Center. He is an expert radiation oncologist who specializes in treating patients with lung and head and neck cancers.

Dr. Juloori received his medical degree from Baylor College of Medicine and completed his residency at Cleveland Clinic. He is board-certified in radiation oncology.

Dr. Juloori is committed to providing innovative therapies to his patients, including stereotactic radiosurgery (SRS), a minimally invasive intervention that offers targeted radiation that minimizes injury to healthy tissue. In addition to his clinical pursuits, Dr. Juloori is an avid researcher, evaluating treatments that can improve outcomes and enhance quality of life. He is investigating the synergistic effects of ablative radiotherapy and immunotherapy in order to find the best solution for each patient. Dr. Juloori is also passionate about clinical trial design, investigating the safety and effectiveness of novel approaches.

Dr. Juloori's research has been published in several high-impact, peer-reviewed journals, such as the *Journal of Clinical Oncology*, *JAMA Oncology*, *Journal of Thoracic Oncology*, *International Journal of Radiation Oncology*, *Biology, and Physics*, *Practical Radiation Oncology*, and *Journal of Neurosurgery*.

Dr. Juloori is a member of the NCCN Head and Neck Cancers Panel and the NCCN Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel.

Billy W. Loo, Jr., MD, PhD, is Professor of Radiation Oncology at Stanford University Medical Center. He is a physician-scientist radiation oncologist and bioengineer who directs the Thoracic Radiation Oncology Program at Stanford Cancer Institute. Additionally, he is a member of the Stanford Molecular Imaging Program and Bio-X.

Dr. Loo earned his medical degree from the University of California, Davis, and his doctorate of philosophy in Bioengineering from the University of California, San Francisco/Berkeley. He completed an internship in internal medicine at Kaiser Permanente Medical Center in San Francisco, and residency in Radiation Oncology at Stanford University.

Dr. Loo is a recognized expert in thoracic cancers. His clinical specialty is precision targeted radiotherapy for lung/thoracic cancers, including stereotactic ablative radiotherapy (SABR). His clinical research is in clinical trials and implementation of new treatment techniques for lung cancer, and development of new medical imaging methods for measuring organ function and predicting response to cancer treatment. He also has developed novel applications of SABR including treatment of pulmonary emphysema and cardiac arrhythmias. He is a Principal Investigator of the FLASH Sciences Lab @Stanford.

Dr. Loo serves as the Vice-Chair of the NCCN Small Cell Lung Cancer Panel, and is a member of the NCCN Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel.

Speaker Biographies

Melina E. Marmarelis, MD, MSCE, is an Assistant Professor of Medicine in Hematology-Oncology at the Hospital of the University of Pennsylvania, the Medical Director of the Penn Mesothelioma and Pleural Disease Program, and the Co-Director of the Molecular Tumor Board. In addition, she is an Innovation Faculty member at the Penn Center for Cancer Care Innovation (PC3I).

Dr. Marmarelis received her medical degree from Harvard Medical School. She completed her residency at Brigham and Women's Hospital and Hematology/Oncology fellowship at the Hospital of the University of Pennsylvania. Dr. Marmarelis is board-certified in internal medicine and medical oncology.

Her research focuses on early phase clinical trials in lung cancer and mesothelioma, determinants of therapy resistance and sensitivity, and molecular characteristics and testing in NSCLC.

Dawn Owen, MD, PhD, is a radiation oncologist who specializes in thoracic malignancies. Dr. Owen is a Professor and Consultant in the Department of Radiology at Mayo Clinic Comprehensive Cancer Center.

Dr. Owen is also active in research on various treatment modalities for early stage and locally advanced lung cancer, safe techniques for reirradiation, proton therapy and spatially fractionated radiation therapy. Dr. Owen has expertise in stereotactic body radiation for oligometastatic and oligoprogressive disease in all body sites including the lung, liver, spine and non-spine bony metastases

Dr. Owen obtained a medical degree from University of Toronto, and residency and internship training from University of British Columbia.

Dr. Owen is a member and Patient Information Medical Reviewer of the NCCN Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel.

Dwight H. Owen, MD, MS, is an Associate Professor of Internal Medicine at The Ohio State University and a member of the Translational Therapeutics Program at the OSU – James Comprehensive Cancer Center. He also serves as Director of the Clinical Treatment Unit and Clinical Trials Processing Laboratory and Leader for the Thoracic Oncology Disease Research Group. He is a medical oncologist who specializes in treating patients with thoracic malignancies including lung cancer, mesothelioma and thymic cancers.

He earned his medical degree at University College Dublin School of Medicine and went on to complete his residency and internship at SUNY Downstate Medical Center, chief residency at Memorial Sloan Kettering Cancer Center, and his fellowship at Ohio State University Wexner Medical Center.

Dr. Owen is involved with several national organizations. He is the co-chair for the American Society of Clinical Oncology's Therapy for Stage IV Non-Small Cell Lung Cancer Living Guidelines group and the co-chair of the Big10 Thoracic Clinical Trials Working Group.

Dr. Owen is a member of the NCCN Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel.

Speaker Biographies

Ana Lucia Ruano Mendez, MD, is an Assistant Professor at the University of Utah School of Medicine. She is a pathologist, specializing in breast in breast and genitourinary pathology with a strong interest in molecular pathology, particularly biomarker testing.

Dr. Ruano Mendez received her medical degree from Universidad Francisco Marroquin. She completed a residency in anatomic and clinical pathology, as well as a fellowship in hematopathology, at Cleveland Clinic. She received additional training in pediatric pathology at University of Utah School of Medicine, and surgical pathology at Roswell Park Cancer Institute.

Dr. Ruano Mendez is board-certified by the American Board of Pathology in anatomic and clinical pathology, hematology, and pediatric pathology.

Dr. Ruano Mendez serves as a member of the NCCN Non-Small Cell Lung Cancer/Mesothelioma/ Thymomas and Thymic Carcinomas Panel.

Beth Sandy, MSN, CRNP, FAPO is a Nurse Practitioner in the Abramson Cancer Center at the University of Pennsylvania, where she has cared for patients for the past 22 years. She specializes in thoracic malignancies. She has been an oncology nurse for 27 years, and is board-certified as an Adult Nurse Practitioner.

Her areas of expertise include the care of patients with lung cancer, specifically targeted therapies and immunotherapies, and biomarker testing in NSCLC.

In addition to regularly presenting and chairing at several national and international nursing and thoracic oncology meetings, Ms. Sandy has been published in a number of peer-reviewed medical and nursing journals and textbooks. She is a board member of APSHO and an Associate Editor for the *Journal of the Advanced Practitioner in Oncology*. She presents and co-chairs at several oncology conferences nationally and internationally.



Jane Yanagawa, MD, is Professor of Thoracic Surgery at the University of California, Los Angeles (UCLA). She is a member of the UCLA Thoracic Oncology Program Tumor Board as well as the UCLA Sarcoma Tumor Board, and has developed a thriving clinical practice in thoracic surgical oncology.

She performs translational lung cancer research as a principal investigator with a laboratory on campus. Her clinical and research backgrounds give her a unique perspective and important skill set for conducting translational research, while her surgical practice gives her access to lung tumors for study.

Dr. Yanagawa earned her medical degree from Baylor College of Medicine. She completed a surgical residency and an internship at UCSD Medical Center. In addition, she completed a fellowship in thoracic surgery at Memorial Sloan Kettering Cancer Center, and a research fellowship at UCLA School of Medicine.

She is a member of the NCCN Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel.

Learn More about NCCN

Who We Are

An alliance of leading cancer centers devoted to patient care, research, and education

Our Mission

To define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives

Our Vision

Access to high-quality, high-value, patient-centered cancer care for all people globally

NCCN Member Institutions

Click here to view the full list of NCCN member institutions.



Learn More

NCCN.org – For Clinicians

NCCN.org/patients – For Patients

Education.nccn.org – CE Portal